Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $268.0 million.

  • Beam Therapeutics' Cash & Equivalents rose 1640.16% to $268.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $268.0 million, marking a year-over-year increase of 1640.16%. This contributed to the annual value of $282.0 million for FY2024, which is 3531.31% down from last year.
  • Latest data reveals that Beam Therapeutics reported Cash & Equivalents of $268.0 million as of Q3 2025, which was up 1640.16% from $282.1 million recorded in Q2 2025.
  • Over the past 5 years, Beam Therapeutics' Cash & Equivalents peaked at $612.0 million during Q3 2021, and registered a low of $97.2 million during Q1 2021.
  • Over the past 5 years, Beam Therapeutics' median Cash & Equivalents value was $268.0 million (recorded in 2025), while the average stood at $299.2 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 34380.69% in 2021, then crashed by 7442.73% in 2022.
  • Quarter analysis of 5 years shows Beam Therapeutics' Cash & Equivalents stood at $560.0 million in 2021, then tumbled by 58.43% to $232.8 million in 2022, then skyrocketed by 87.27% to $435.9 million in 2023, then crashed by 35.31% to $282.0 million in 2024, then fell by 4.97% to $268.0 million in 2025.
  • Its Cash & Equivalents was $268.0 million in Q3 2025, compared to $282.1 million in Q2 2025 and $527.9 million in Q1 2025.